NUREXONE BIOLOGIC INC. Cash Flow Conversion Efficiency

Latest as of December 2025: -0.426x

NUREXONE BIOLOGIC INC. cash flow conversion efficiency. Based on the latest financial reports, NUREXONE BIOLOGIC INC. (J90) has a cash flow conversion efficiency ratio of -0.426x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.17 Million ≈ $-1.37 Million USD) by net assets (€2.76 Million ≈ $3.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of NUREXONE BIOLOGIC INC. (2021–2025)

Cash flow conversion efficiency of NUREXONE BIOLOGIC INC. from 2021 to 2025. This chart illustrates how NUREXONE BIOLOGIC INC.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View NUREXONE BIOLOGIC INC. stock quote for real-time trading data and today's change.

NUREXONE BIOLOGIC INC. Cash Flow Conversion Ratio Explained

NUREXONE BIOLOGIC INC. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

NUREXONE BIOLOGIC INC. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of NUREXONE BIOLOGIC INC. ranked by their cash flow conversion efficiency. Also see how much is NUREXONE BIOLOGIC INC. worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Commerce Resources Corp. V:CCE	-0.001x
Ege Seramik Sanayi ve Ticaret AS IS:EGSER	-0.103x
Nureca Limited NSE:NURECA	0.022x
Sun Race Sturmey-Archer Inc TW:1526	0.044x
Italy Innovazioni SpA PA:MLITN	N/A
Autech Corporation KQ:067170	-0.009x
KCP Sugar and Industries Corporation Limited NSE:KCPSUGIND	0.089x
Blue Star Helium Ltd AU:BNL	-0.252x

Annual Cash Flow Conversion Efficiency for NUREXONE BIOLOGIC INC. (2021–2025)

The table below shows the annual cash flow conversion efficiency of NUREXONE BIOLOGIC INC. from 2021 to 2025. Review J90 financial flexibility score to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€2.76 Million ≈ $3.22 Million	€-4.51 Million ≈ $-5.27 Million	-1.636x	+41.07%
2024-12-31	€1.76 Million ≈ $2.06 Million	€-4.89 Million ≈ $-5.71 Million	-2.776x	+82.16%
2023-12-31	€189.00K ≈ $220.96K	€-2.94 Million ≈ $-3.44 Million	-15.561x	-747.60%
2022-12-31	€2.10 Million ≈ $2.45 Million	€-3.85 Million ≈ $-4.50 Million	-1.836x	-75.39%
2021-12-31	€1.18 Million ≈ $1.38 Million	€-1.23 Million ≈ $-1.44 Million	-1.047x	--

About NUREXONE BIOLOGIC INC.

F:J90 Germany Biotechnology

Market Cap

$30.78 Million

€26.33 Million EUR

Market Cap Rank

#23485 Global

#2051 in Germany

Share Price

€0.29

Change (1 day)

-2.72%

52-Week Range

€0.24 - €0.47

All Time High

€0.88